APLT实时信号 | 通过Getagraph.com最大化利润

购买 107559 min ago

@ $2.66

发出时间: 15 Feb 2024 @ 03:44

回报率: 60.90%

上一信号: Feb 15 - 02:41

上一信号: 出售

回报率: -3.45 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications...

Stats
今日成交量	429 224
平均成交量	1.83M
市值	488.96M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $-0.0700 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.01
ATR14	$0.00600 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-12	Hooks Corwin Dale	Buy	300 000	Common Stock
2024-04-12	Hooks Corwin Dale	Buy	0
2024-03-14	Shendelman Shoshana	Sell	318 573	Common Stock
2024-03-14	Perfetti Riccardo	Sell	110 804	Common Stock
2024-03-14	Hansard Adam	Sell	48 871	Common Stock

INSIDER POWER
41.30
Last 97 transactions
Buy: 24 985 894 \| Sell: 4 549 161

音量相关性

長: -0.60 (weak negative)

短: -0.63 (weak negative)

Signal:(27.237) Neutral

Applied Therapeutics Inc 相关性

10 最正相关
NISN	0.932
EYPT	0.926
SEAC	0.906
CYCN	0.901
SCR	0.891
ADMP	0.889
ICON	0.889
WORX	0.889
ACLX	0.889
LEGN	0.886

10 最负相关
CHDN	-0.91
REYN	-0.884
SCOR	-0.882
VTRU	-0.881
DCRC	-0.877
SGLB	-0.872
ALGM	-0.866
ENLV	-0.863
MTEX	-0.863
DCGO	-0.862

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Applied Therapeutics Inc 相关性 - 货币/商品

-0.41
( neutral )

0.15
( neutral )

0.00
( neutral )

-0.11
( neutral )

0.37
( neutral )

-0.15
( neutral )

Applied Therapeutics Inc 财务报表

Annual	2023
营收:	$9.99M
毛利润:	$9.64M (96.47 %)
EPS:	$-1.420

FY	2023
营收:	$9.99M
毛利润:	$9.64M (96.47 %)
EPS:	$-1.420

FY	2022
营收:	$0
毛利润:	$-441 000 (0.00 %)
EPS:	$-2.16

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-4.12

Financial Reports:

No articles found.

Applied Therapeutics Inc

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.